Core Insights - Haoxi Health Technology Limited has launched a customized livestreaming agency strategy through its subsidiary, Haoxi Beijing, to enhance its business development in the healthcare sector [1][4] - The new livestreaming services are designed to meet the growing demand for personalized and high-quality offerings in the medical aesthetics market, particularly focusing on "light medical aesthetics" treatments [2][4] Company Overview - Haoxi Health Technology Limited is an online marketing solution provider based in Beijing, specializing in the healthcare industry, and aims to reduce costs and increase efficiency for advertisers [5] - The company has established a stable advertising delivery model based on long-term client servicing experience, which supports its new service offerings [2][5] Service Details - The livestreaming agency services encompass a full-cycle approach, including pre-campaign planning, livestream initiation, and post-campaign analysis, tailored for the medical aesthetics segment [2][4] - The services include account setup, content planning, short video marketing, livestream ad strategy, and platform resource integration, aimed at enhancing brand building and online conversion rates [4]

Core Points - Haoxi Health Technology Limited has regained compliance with Nasdaq Listing Rule 5550(a)(2) after its Class A ordinary shares maintained a minimum bid price of $1.00 for 10 consecutive business days [1][2] - The compliance determination was made following the closing bid price of the Company's Ordinary Shares being at or above $1.00 from January 27, 2025, to February 7, 2025 [2] Company Overview - Haoxi Health Technology Limited is an online marketing solution provider based in Beijing, China, focusing on the healthcare industry [3] - The Company specializes in online short video marketing and offers one-stop online marketing solutions to help advertisers acquire and retain customers on popular Chinese platforms such as Toutiao, Douyin, WeChat, and Sina Weibo [3] - The growth of the Company is driven by the rise of news feed ads and the rapid development of the healthcare sector, with a commitment to reducing costs and increasing efficiency for advertisers [3]

Core Viewpoint - Haoxi Health Technology Limited has announced a reverse share split of its ordinary shares at a ratio of 1-for-25, which was approved by shareholders and will take effect on January 27, 2025 [1][2]. Group 1: Reverse Share Split Details - The reverse share split will combine every 25 shares of Class A and Class B ordinary shares into one share, reducing the total outstanding Class A shares from approximately 53.29 million to about 2.13 million and Class B shares from approximately 17.27 million to about 0.69 million [2]. - The company's Articles and Memorandum of Association have been amended to proportionately reduce the number of authorized shares and adjust the par value of the post-reverse share split ordinary shares to $0.0025 per share [3]. - No fractional shares will be issued; instead, entitlements to fractional shares will be rounded up to the nearest whole share [3]. Group 2: Market Impact and Expectations - Following the reverse share split, the Class A ordinary shares are expected to trade at approximately twenty-five times the price per share prior to the split, although the company cannot guarantee that this price will be maintained [4]. - The new CUSIP number for the Class A ordinary shares will be G4290F118, and trading will commence on an adjusted basis on the Nasdaq Capital Market [1][2]. Group 3: Company Overview - Haoxi Health Technology Limited is an online marketing solution provider based in Beijing, China, focusing on the healthcare industry [6]. - The company's growth is driven by the rise of news feed ads and the rapid development of the healthcare sector, offering one-stop online marketing solutions, particularly in online short video marketing [6].

BEIJING, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Haoxi Health Technology Limited (the “Company” or “HAO”), an online marketing solution provider headquartered in Beijing, China, today announced the Company’s wholly owned subsidiary Beijing Haoxi Digital Technology Co., Ltd. (“Beijing Haoxi”) was awarded a Recharge Service Framework Contract (the “Contract”) to provide comprehensive digital advertising services with a budget of RMB30 million for Tengyuan Media Advertising Co., Ltd. (“Tengyuan") and its clients. Pu ...

Core Viewpoint - Haoxi Health Technology Limited reported significant financial growth for the fiscal year ended June 30, 2024, with net revenue increasing by 72% to $48.52 million, driven by a rise in average revenue per client and an expanded customer base [2][3]. Financial Highlights - Net revenue for fiscal 2024 reached $48.52 million, up from $28.23 million in 2023, marking a 72% increase [2][3][7]. - Gross profit increased by 33% to $2.75 million, compared to $2.06 million in the previous fiscal year [2][10]. - Net income grew by 33% to $1.29 million, up from $0.97 million in fiscal 2023 [2][13]. Revenue Generation - The company generates revenue through one-stop online marketing solutions, including traffic acquisition, content production, data analysis, and advertising campaign optimization [6]. - The increase in revenue is attributed to a rise in average revenue per client from $71,830 in fiscal 2023 to $89,355 in fiscal 2024, alongside an increase in the customer base from 393 to 543 clients [3][7]. Cost Structure - Cost of revenue increased by 75% to $45.77 million, in line with revenue growth [9][10]. - Selling and marketing expenses rose by 30% to $41,613, while general and administrative expenses increased by 17% to $911,531 [11][12]. Recent Developments - The company announced a strategic partnership with Gauss Intelligence to leverage AI capabilities for marketing solutions [4]. - A follow-on offering raised $12 million, enhancing the company's financial position [5]. Cash Position - As of June 30, 2024, the company had cash and cash equivalents of $6.66 million, a significant increase from $1.20 million in the previous year [13][18].

Core Insights - Haoxi Health Technology Limited (HAO) announced preliminary unaudited financial results for FY24, projecting significant revenue growth attributed to strategic developments in online advertising solutions, particularly in short video formats and news feed ads [1][2] Financial Performance - Revenue for FY24 is projected at approximately $48.52 million, reflecting a 72% increase from $28.23 million in FY23 [1] - Gross profit is estimated at approximately $2.75 million for FY24, a 33.4% increase from $2.06 million in FY23 [1] - Net income is projected to be approximately $1.29 million for FY24, marking a 33.2% increase from $0.97 million in FY23 [1] - Total assets increased to approximately $15.51 million as of June 30, 2024, up from $4.46 million at the end of FY23, indicating growth in operational scale and capital utilization post-IPO [1] Business Strategy and Market Position - Since its IPO in January 2024, HAO has consistently grown its core business, benefiting from the demand for targeted healthcare advertising in China [2] - The company aims to strengthen its position in the digital healthcare advertising market through established relationships with major media platforms and expertise in short video ad optimization [2] - HAO is committed to capitalizing on the expanding healthcare sector in China, focusing on ad placement strategies and enhancing service offerings [2][4]

Company Overview - Haoxi Health Technology Limited is an online marketing solution provider based in Beijing, China, specializing in the healthcare industry [4] - The company focuses on online short video marketing and aims to help advertisers acquire and retain customers on popular Chinese platforms such as Toutiao, Douyin, WeChat, and Sina Weibo [4] Recent Developments - Haoxi Beijing, a wholly-owned subsidiary of Haoxi Health Technology, signed a Framework Contract with Wuhan Yiya Simei Dental Clinic for advertising services on April 28, 2024 [1][2] - The contract stipulates that Haoxi Beijing will provide comprehensive advertising services on social media platforms, including Douyin, Toutiao, and Xigua Video, with a minimum cooperation fee of RMB40 million (approximately $5.5 million) [2] Strategic Insights - The CEO of Haoxi Health Technology emphasized the importance of social media advertising, which allows for real-time monitoring and optimization of advertising effectiveness [3] - The company aims to leverage data analysis to enhance advertising strategies and improve the overall patient experience for Yiya Dental [3] - Haoxi Health Technology is looking to expand its client base and explore innovative advertising distribution strategies to achieve sustainable business growth [3]

Core Viewpoint - The communication services sector has several oversold stocks, presenting potential buying opportunities for undervalued companies [1] Group 1: AMC Entertainment Holdings, Inc. (AMC) - AMC entered an equity distribution agreement to sell shares with an aggregate offering price of $250 million [2] - The stock has fallen approximately 32% over the past month, reaching a 52-week low of $2.94 [2] - The RSI value for AMC is 26.18, indicating it is considered oversold [2] Group 2: Haoxi Health Technology Limited (HAO) - Haoxi Health Technology closed a $9.6 million initial public offering on January 30 [3] - The stock has decreased around 38% in the last month, with a 52-week low of $4.25 [3] - The RSI value for HAO is 29.15, suggesting it is also oversold [3] Group 3: Sirius XM Holdings Inc. (SIRI) - SiriusXM is set to release its Q1 2024 operating and financial results on April 30 [4] - The stock has dropped about 12% over the past five days, hitting a 52-week low of $3.32 [4] - The RSI value for SIRI is 12.90, indicating a significant oversold condition [4]

BEIJING, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Haoxi Health Technology Limited (the "Company" or "HAO"), an online marketing solution provider headquartered in Beijing, China, today announced the closing of its initial public offering (the "Offering") of 2,400,000 Class A ordinary shares (the "Ordinary Shares") at an initial public offering price of $4.00 per share for total gross proceeds of $9,600,000, before deducting underwriting discounts and other offering expenses. The Offering closed on January 30, 2024 ...

BEIJING, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Haoxi Health Technology Limited (the "Company" or "HAO"), an online marketing solution provider headquartered in Beijing, China, today announced the pricing of its initial public offering (the "Offering") of 2,400,000 Class A ordinary shares (the "Ordinary Shares") at a public offering price of $4.00 per share ("Public Offering Price") for total gross proceeds of $9,600,000, before deducting underwriting discounts and other offering expenses. The Ordinary Shares ha ...